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ABSTRACT
Ample evidence has suggested that extracellular a-synuclein aggregates would play key roles in the
pathogenesis and progression of Parkinsonian disorders (PDs). In the present study, we investigated
whether mesenchymal stem cells (MSCs) and their derived soluble factors could exert neuroprotec-
tiveeffects viaproteolysis of extracellulara-synuclein.Whenpreformeda-synucleinaggregateswere
incubated withMSC-conditionedmedium,a-synuclein aggregates were disassembled, and insoluble
andoligomeric formsofa-synucleinweremarkedly decreased, thus leading toa significant increase in
neuronal viability. In an animal study,MSC orMSC-conditionedmedium treatment decreased the ex-
pression ofa-synuclein oligomers and the induction of pathogenica-synucleinwith an attenuation of
apoptotic cell death signaling. Furthermore, we identified that matrix metalloproteinase-2 (MMP-2),
a soluble factor derived from MSCs, played an important role in the degradation of extracellular
a-synuclein. Our data demonstrated thatMSCs and their derivedMMP-2 exert neuroprotective prop-
erties through proteolysis of aggregated a-synuclein in PD-related microenvironments. STEMCELLS
TRANSLATIONAL MEDICINE 2016;5:1–13
SIGNIFICANCE
Misfolded a-synuclein can be released from cells and transmitted from one brain area to others
through cell-to-cell propagation in Parkinson’s disease (PD). Therefore, extracellular a-synuclein ag-
gregateswould play key roles in the pathogenesis and progression of PD. Proteolysis is the protective
mechanism bywhichmesenchymal stem cells (MSCs) exert neuroprotective properties through pro-
teolysis of aggregated a-synuclein into soluble forms, which is the actual protective mechanism, and
matrixmetalloproteinase-2 is oneof theMSC-derived soluble factors that cleavedpreformed fibrils of
a-synuclein. The data suggest that the disassembly of a-synuclein aggregation to control PD-related
microenvironments using MSCs may have a significant impact on future PD treatment strategies.
INTRODUCTION
Parkinson’s disease (PD) is characterized patholog-
ically by the progressive loss of dopaminergic neu-
rons in the substantia nigra region of the midbrain
and the presence of Lewy bodies, proteinaceous
fibrillar cytoplasmic inclusions that are composed
mainly of aggregateda-synuclein [1]. Since genetic
analyses have identified three missense mutations
in the a-synuclein gene (SNCA), as well as duplica-
tion and triplication of the locus containing SNCA in
familial forms of PD [2, 3], the pathophysiological
role of a-synuclein has been a target of extensive
investigations in PD research.
Other than missense mutations in a-synuclein,
many other factors and events have been reported
to influence the fibrillization of a-synuclein, and
thesecanbe involved in the formationofa-synuclein
inclusions in sporadic PD. a-Synuclein consists of
140 amino acids and is divided into the N-terminal
region (amino acid residues 1–60), the central region
(amino acids residues 61–95), and the C-terminal re-
gion (amino acid residues 96–140) [4]. Although the
precise role of a-synuclein in normal function is un-
known, it exists natively as an unfolded cytoplasmic
protein in neuronal synaptic terminals. However,
there is evidence that overexpression andmisfolding
of a-synuclein directly increases cell death and
toxicity in mammalian cells, leading to a decrease
in neurite outgrowth and cell adhesion due to dis-
rupted degradation systems [5]. The a-synuclein
aggregates of monomeric form, oligomeric inter-
mediate, or fibrillar form are thought to be a crit-
ical step in the pathogenesis of PD aswell as other
a-synucleinopathies of multiple-system atrophy
and dementia with Lewy bodies, although the
aDepartment of Neurology,
Yonsei University College of
Medicine, Seoul, Republic of
Korea; bSeverance
Biomedical Science Institute,
Yonsei University, Seoul,
Republic of Korea;
cDepartmentofPharmacology,
Ajou University School of
Medicine, Suwon, Republic
of Korea
Correspondence: Phil Hyu Lee,
M.D., Ph.D., Department of
Neurology, Yonsei University
College of Medicine, 250
Seongsanno, Seodaemun-gu,
Seoul 120-752, Republic of Korea.
Telephone: 82-2-2228-1608;
E-Mail: phisland@chol.net
Received March 3, 2016;
accepted for publication August
29, 2016.
©AlphaMed Press
1066-5099/2016/$20.00/0
http://dx.doi.org/
10.5966/sctm.2016-0111
STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–13 www.StemCellsTM.com ©AlphaMed Press 2016
TISSUE ENGINEERING AND REGENERATIVE MEDICINE
This is an open access article
under the terms of the Creative
Commons Attribution License,
which permits use, distribution
and reproduction in any medium,
provided the original work is
properly cited.
IFICANCE STATEMENT
7;6:949–961
e m
ReceivedMarch 3, 2016;
accepted for publication August
29, 2016; publishedOnline First
onOctober 11, 2016.
ID: srinivasanv Time: 19:55 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTM/Vol00603/170047/Comp/APPFile/JW-SCTM170047
LLS SL I L I I 7;:949–961 www.StemCellsTM.com Oc 2016 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
toxicity seems to differ depending on the aggregate form [6].
Thus, similar to other proteinopathies in the central nervous sys-
tem, a-synucleinopathies share key molecular characteristics of
toxicity of protein aggregates.
Both oligomeric and monomeric a-synuclein have been de-
tected in cerebrospinal fluid and plasma samples fromPDpatients,
suggesting that small aggregatesofa-synucleinaccess theextracel-
lular space [7–9].Moreover, previous animal and clinical data have
suggested thatmisfoldeda-synuclein can be released from cells by
exocytosis and could then be transmitted from one brain area into
others through cell-to-cell propagation [10, 11]. Experimental evi-
denceshowed thatanaggregated formofextracellulara-synuclein
can induce neuroinflammation-mediated neurotoxic signaling
through microglial activation and release of proinflammatory fac-
tors [12, 13]. Accordingly, removal of aggregateda-synuclein from
theextracellular space is important for neuronal survival, and, thus,
strategies targeting modulation of aggregated a-synuclein in the
extracellular space may be future therapeutic options in patients
with PD.
Mesenchymal stem cells (MSCs) are multipotent stem cells
that reside in many adult tissues, such as adult bone marrow,
liver,muscle connective tissue, amniotic fluid, placenta, umbilical
cord blood, or dental pulp, that are capable of differentiating
into various cell types under appropriate conditions. Additionally,
MSCs secrete various cytotropic factors, including neurotrophic
growth factors, chemokines, cytokines, and extracellular matrix
protein, which, in turn, exert neuroprotective effects [14–17].
Our previous studies showed that MSCs have potent neuropro-
tective effects in animalmodels of PD throughmodulation of neu-
roinflammation, inhibition of apoptotic cell death, increases in
neurogenesis and neuronal differentiation, inhibition of cell-to-
cell transmission of extracellular a-synuclein, and enhancement
of autophagy [18–24]. In the present study, we evaluated
whether MSCs would degrade aggregated a-synuclein and thus
exert a neuroprotective effect throughmodulation of proteolytic
cleavage of a-synuclein, using in vitro and in vivo models of PD.
Furthermore, we determined that matrix metalloproteinase-2
(MMP-2), one of the biological molecules secreted from MSCs,
plays a crucial role in the modulation of aggregated a-synuclein.
MATERIALS AND METHODS
a-Synuclein Aggregate Preparation and Fluorescent
Dye Labeling
Recombinant a-synuclein (200 mM in phosphate-buffered saline
[PBS]) was agitated at 37°C (250 rpm) for 14 days. After brief sonica-
tion, the protein was incubated for another 7 days. Aggregated pro-
tein was collected by ultracentrifugation at 200,000g for 1 hour, and
the pellet was resuspended in PBS with brief sonication. Alexa Fluor
488labelingofa-synucleinaggregatewasperformedaccordingtothe
manufacturer’s instructions (Thermo Fisher Scientific Life Sciences,
Oakwood Village, OH, https://www.thermofisher.com). Briefly, ag-
gregate proteins were incubated with 24-fold molar excess of Alexa
Fluor 488 at room temperature for 1 hour. Excess unbound Alexa
Fluor 488 dye was removed by passing through a desalting column.
MSCs and SH-SY5Y Culture
Frozen vials of characterized human MSCs at passage 2 were
obtained from the Severance Hospital Cell Therapy Center (Seoul,
South Korea; Institutional Review Board no. 4-2008-0643). Human
neuroblastoma cell line SH-SY5Y cells were obtained from the Ko-
rean Cell Line Bank (Seoul, South Korea). Both MSCs and SH-SY5Y
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, GE Healthcare Life Sciences, Piscataway, NJ, http://www.
gelifesciences.com) supplemented with 10% fetal bovine serum
(FBS, GE Healthcare) and an antibiotic mixture of penicillin and
streptomycin (1%, GE Healthcare). When these cells reached
70%–80% confluence, they were trypsinized and subcultured.
These cells were cultivated in a humidified incubator at 37°C
and 5% CO2 before use. For in vitro experiments, SH-SY5Y
was plated at a density (of 1.53 104 cells per cm2) and treated
with conditioned medium (CM).
Preparation of Cell CM and Materials
CMwasobtained fromMSCs at passage5 andSH-SY5Y cells. To col-
lect the CM, MSCs and SH-SY5Y cells were first cultured in FBS-
DMEM, 100U/ml penicillin, and 100mg/ml streptomycin and then
incubated at 37°C in a humid atmosphere with 5% CO2. When the
cells reached 70%–80% confluence, they werewashed three times
with 13PBS incubated in serum-freemedium (OPTIMEM, Thermo
Fisher) at 37°C in a humid atmosphere with 5% CO2 for 72 hours.
The medium was collected and cleared by 10-minute centrifuga-
tion at 1,200g; protein concentrationwas adjustedwithOPTIMEM
to 200 mg/ml and sterilized by filtration through a 220-nm syringe
filter (Corning, Corning, NY, http://www.corning.com) and stored
at 220°C until used. The media of MSCs and SH-SY5Y cells were
both assumed to contain various paracrine molecules. For in vitro
experiments, recombinant human MMP-2 protein was obtained
from Neuromics (Edina, MN, http://www.neuromics.com)
(supplemental online Fig. 1). The purified a-synuclein fibrils (10 mM)
were incubated with MMP-2 (2.2 mg; 1:0.02 substrate/enzyme
molar ratio) in an MMP-reaction buffer (20 mM Tris-HCl, pH
7.5, 150 mM NaCl, 5 mM CaCl2, and 0.5 mM ZnCl2) and with
CM in a humidified incubator at 37°C for 3 days, and the reaction
productswere subjected tosodiumdodecyl sulfatepolyacrylamide
gel electrophoresis (SDS-PAGE) and structural analysis. Reaction
mixtureswere then centrifuged at 65,000 rpm for 1 hour, superna-
tants were saved (soluble fraction), and pellets (insoluble fraction)
were washed once with PBS. For in vivo injection, CM from
13106 cellswas centrifuged to removecell debris and concentrated
by using VIVASPIN6 centrifugal filter devices (Sartorius Stedim,
Goettingen, Germany, https://www.sartorius.com) at 4°C for 1 hour.
Two-Dimensional PAGE
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)
was basically performed as described previously [25]. Briefly,
200 mg of protein extract was separated by isoelectric focusing
byusing an immobilized pHgradient stripwith a nonlinear pHgra-
dient of 4–10 (Genomine, Pohang, Korea, http://www.genomine.
co.kr) for the first dimension and then SDS-PAGE (26 3 20-cm
format) for the second dimension. Proteins were detected by al-
kaline silver staining as described previously [26]. Image analysis
and quantification of protein spots were performed by using the
PDQuest software (Bio-Rad, Hercules, CA, http://www.bio-rad.com).
The quantity of protein in each spot was normalized relative to the
total valid spot intensity.
Protein Identification by Mass Spectrometry
For protein identification by peptide mass fingerprinting (PMF),
protein spots were excised, digested with trypsin (Promega,
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Madison, WI, http://www.promega.com), mixed with a-cyano-
4-hydroxycinnamic acid in 50% acetonitrile/0.1% trifluoroacetic
acid, and subjected to matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF/MS) analysis by
Microflex LRF 20 (Bruker Daltonics, Seoul, South Korea, https://
www.bruker.com) as described [27]. Spectra were collected from
300 shots per spectrum over the m/z range 600–3,000 and
calibrated by two-point internal calibration using trypsin autodi-
gestion peaks (m/z 842.5099, 2,211.1046). The peak list was gen-
erated by using Flex Analysis 3.0 (Bruker Daltonics). The
thresholds used for peak-picking were as follows: 5,000 for
minimum resolution of monoisotopic mass, 2.5 for the signal-
to-noise ratio. The profound (http://prowl.rockefeller.edu/prowl-
cgi/profound.exe) programwas used to search the human National
Center for Biotechnology Information Nonredundant database
for protein identification. The following parameters were used for
the database search: trypsin as the cleaving enzyme, a maximum
of onemissed cleavage, iodoacetamide as a completemodification,
oxidationasapartialmodification,monoisotopicmasses, andamass
tolerance of60.1 Da. PMF acceptance criteria were based on prob-
ability scoring.
Thioflavin Fluorescence Assay
A stock solution of 100 mM Thioflavin T (ThT, Sigma-Aldrich, St.
Louis, MO, http://www.sigmaaldrich.com) was prepared and fil-
tered through a 0.2-mm polyether sulfone filter (Pall Corp., Port
Washington, NY, http://www.pall.com). To each well was added
40ml ofa-synuclein with CMand 50ml of ThT (10mM) in 100mM
glycine-NaOH (pH 8.5). A black 96-well microplate (SPL Life Sci-
ences Co., Pocheon, South Korea, http://spllabware.en.ec21.
com) was centrifuged briefly at 500 rpm to remove air pockets
and equilibrated for 5 min. Fluorescence was measured with
a Varioskan Flash (Thermo Fisher) with excitation at 450 nm
(bandwidth, 10 nm) and emission at 482 nm (bandwidth, 10 nm).
Electron Microscopy
Samples were prepared from 5-ml aliquots of relevant aggrega-
tion, and reaction was absorbed onto a glow-discharged carbon
support film, washed twice using 100 ml of distilled water, and
negatively stained with 2% (wt/vol) uranyl acetate. Grids were
examined at 3100,000 to 3150,000 magnification, and images
were examined with a JEM-100CX electron microscope (JEOL,
Tokyo, Japan, www.jeol.co.jp) at 80 kV.
Cell Viability Analysis
SH-SY5Y cells were harvested and plated in 96-well polystyrene
plates (Corning) at a concentration of 1.5 3 104 cells per 100 ml
of medium per well. Plates were incubated at 37°C for 24 hours
to allow cells to attach. After 24 hours, themediumwas exchanged
with 100 ml of the preincubated mixtures of a-synuclein with
CM. The samevolumeofDMEMwasadded to the control cultures.
Plates were then incubated at 37°C for an additional 24 and
48 hours. Cell viability was measured by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) reduction assays essen-
tially as described [28]. Briefly, after the cells were incubated
with the variousmedium samples, MTTwas added to a final con-
centration of 0.5 mg/ml. After incubation at 37°C for 3 hours,
the plateswere centrifuged, and themediumwas aspirated from
each well. The absorbance was measured by an enzyme-linked im-
munosorbent assay (ELISA)microplate reader (VersaMax,Molecular
Devices, Sunnyvale, CA, http://www.moleculardevices.com) at 490
nm. Cell viability was calculated by dividing the absorbance of wells
containing samples (corrected for background) by the absor-
bance of wells containing medium alone (corrected for
background).
Reverse-Transcription Polymerase Chain Reaction
To knock downMMP-2 inMSCs, anMMP-2 small interfering RNA
(siRNA) construct (Santa Cruz Biotechnology, Santa Cruz, CA,
http://www.scbt.com) was purchased and tested for knockdown
efficiency. MSCs were plated at a density of 13 105 per cm2 and
incubatedwith 8ml of 20mMsiRNA (final concentration 40nM) in
100ml of OPTIMEM (Thermo Fisher) containing 10ml of Lipofect-
amine 2000 (Thermo Fisher). After 72 hours, total RNA was
extracted from theMSCs by using TRIzol reagent (Thermo Fisher)
in accordance with the manufacturer’s protocol. An equal
amount of RNA (1 mg) in each experiment was reverse-
transcribed by using amfiRivert cDNA Synthesis Premix (Gen-
DEPOT, Barker, TX, http://www.gendepot.com). Subsequently,
2 ml of cDNA were used as a template for reverse-transcription
polymerase chain reaction (RT-PCR) analysis in and amfiRivert
1-Step RT-PCR Kit (GenDEPOT). PCR was performed by using 10
pmol of primers for human MMP-2 (forward, 59-CATACAAAGG-
GATTGCCAGGA -39; reverse, 59-GGTATTGCACTGCCAACTCT-39).
After an initial denaturation at 95°C for 2 minutes, 30 cycles
of PCR were performed, consisting of denaturation (1 minute,
95°C), annealing (1 minute, 54°C), and extension (1 minute, 72°C),
followed by a final extension step (5 minutes, 72°C). The PCR
products were separated by electrophoresis on 2% agarose
gels (iNtRON Biotechnology, Seongnam, South Korea, http://
intronbio.com) and stained with ethidium bromide (Sigma-Aldrich).
Gels were examined under UV illumination (DNR Bio-Imaging
Systems, Jerusalem, Israel, http://www.dnr-is.com). Density was
measured by using the Image Gauge software (Version 4.0,
Fujifilm Advanced Research Laboratories, Ashigarakami, Japan,
http://www.fujifilm.com).
Animal Study
All procedures were performed in accordance with the Labora-
tory Animals Welfare Act, the Guide for the Care and Use of Lab-
oratory Animals, and the Guidelines and Policies for Rodent
Experiment provided by the Institutional Animal Care and Use
Committee at the Yonsei University Health System. Male
C57BL/6miceaged16weeks (OrientBio, Seongnam, SouthKorea,
www.orient.co.kr) were acclimated in a climate-controlled room
with a constant 12-hour light/dark cycle (12-hour lights on) for
1 week before the initiation of drug administration. To evaluate
the modulatory effects of MSCs in an 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP)-induced animal model of PD,
mice were injected with MPTP (intraperitoneal injection [i.p.),
30 mg/kg, daily for 5 days]. The mice were randomly divided into
three groups (n = 5per group): (a) control, (b)MPTP, and (c)MPTP
andMSC.Mice in theMPTPgroupwere injectedwith saline via tail
vein at 3 days after final MPTP injection. Mice in the MSC group
were subjected toMSCs into the tail vain (13106 cells per 200ml)
at 3 days after final MPTP injection. All mice were sacrificed at 7
days after MSC injection. To create an a-synuclein-inoculated
model, a-synuclein (5 mg per mouse) with or without dynasore
(80mMpermouse)was administered via the neocortex and stria-
tum in accordance with the procedure described previously with
Oh, Kim, Park et al. 3
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minor modifications [11]. Briefly, mice were anesthetized
with isoflurane (Baxter, Utrecht, The Netherlands, http://www.
baxter.nl), anda-synuclein with or without dynasore were slowly
injected bilaterally into the cortex (0.4 mm posterior to bregma,
1.3mmlateral tomidline, and0.6mmventral to thebrain surface)
and striatum (0.2 mm posterior to bregma, 62.0 mm lateral to
midline, and 2.6 mm ventral to the brain surface) by using
a stainless-steel injection needle (26 gauge) connected to a
10-ml Hamilton microsyringe (Hamilton, Reno, NV, http://www.
hamiltoncompany.com). Theneedlewas left inplace for 10minutes
before being withdrawn slowly. Then, to evaluate whether
MSCs disassemble extracellular a-synuclein aggregates, the
mice were randomly divided into three groups (n = 5 per group):
(a) control, (b)a-synuclein, and (c)a-synuclein andMSC.Mice in
the a-synuclein group were injected with saline via tail vein at 1
day after a-synuclein inoculation (postoperative day 1). Mice in
theMSCgroupwere subjected toMSCs into the tail vain (13 106
cells per 200 ml) on postoperative day 1, and all mice were sac-
rificed on postoperative day 7 (cortical injection group) or 30
(striatal injection group). Finally, to evaluate themodulatory ef-
fects of MSCs on extracellular a-synuclein aggregates, the mice
were randomly divided into three groups (n = 5 per group): (a)
fresh medium, (b) MSC-CM, and (c) MMP-2. Mice in each group
were subjected to medium delivery on postoperative day 1, and
all mice were sacrificed on postoperative day 4.
Brain Sample Preparation
For immunochemical analysis, all mice were deeply anesthetized
with chloral hydrate (I.P., 0.4 g/kg; Sigma-Aldrich) and then per-
fused with 4% paraformaldehyde (Sigma-Aldrich) in 0.1 M phos-
phate buffer (pH 7.4). The brains were embedded in paraffin, and
coronal sections 4-mm thick were then cut and placed on slides.
Immunocytochemistry and Immunohistochemistry
SH-SY5Y cells and brain sections were washed twice in PBS and
incubated in 0.2% Triton X-100 (Sigma-Aldrich) for 30 minutes
at room temperature. Theywereblockedwith 0.5%bovine serum
albumin (BSA; Sigma-Aldrich) for 30minutes. After blocking, they
were rinsed three timeswith0.5%BSAand incubatedovernight at
4°Cwith specific primary antibodies. The primary antibodies used
wereas follows:mouseanti-a-synuclein (EMDMillipore, Billerica,
MA, http://www.emdmillipore.com), rabbit anti-a-synuclein
(phospho S129, Abcam, Cambridge, MA, http://www.abcam.
com), rabbit anti-MMP-2 (Abcam), mouse anti-tyrosine hydroxy-
lase antibody (TH, Sigma-Aldrich), and mouse anti-nuclear mitotic
apparatus protein antibody (NuMA, EMDMillipore). Immunofluo-
rescence labelingwascarriedoutby incubating the cellswith rabbit
anti-IgG Alexa Fluor 555 (Thermo Fisher Scientific Life Sciences),
mouse anti-IgG Cy-3 (EMD Millipore), rabbit anti-IgG Cy-3 (EMD
Millipore), and rabbit anti-IgG FITC (EMDMillipore). The cell nuclei
were counterstained with 49,6-diamidino-2-phenylindole (Thermo
Fisher). The TH antibodies were detected with 0.05% diaminoben-
zidine (Vector Laboratories, Burlingame, CA, http://vectorlabs.
com). The immunostained cells were analyzed by using bright-
field microscopy and viewed under a Zeiss LSM 700 confocal imag-
ing system (Zeiss, Stuttgart, Germany, http://www.zeiss.com). To
analyze the localizationsof antigens indouble-stained samples, im-
munofluorescence images were created from the same tissue sec-
tions and merged by using the Zeiss ZEN software.
Western Blotting
Brain tissues were dissolved in ice-cold RIPA buffer (50 mM Tris-
HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630,
0.5% sodium deoxycholate, and 0.1% SDS) (Sigma-Aldrich) plus
protease inhibitor cocktail (Sigma-Aldrich). The lysates were
centrifuged at 4°C for 20 min (14,000g), and supernatants were
transferred to fresh tubes. For soluble and insoluble fractions,
5ml of 10% Triton X-100was added to 45ml of protein to produce
a 1% solution of Triton X-100 and vortexed. The extraction
was performed for 15 minutes on ice, and the cell extract was
centrifuged at 14,000g for 10 minutes. The supernatant (soluble
fraction) was saved, and the pellet (insoluble fraction) was resus-
pended in 10 ml of RIPA buffer. Briefly, 50 and 100 mg of protein
were separated by SDS-gel electrophoresis and transferred onto
hydrophobic polyvinylidene difluoride membranes (GE Health-
care). The membranes were blocked in nonfat milk (BD, Franklin
Lakes, NJ, http://www.bd.com). Membranes were probed with
the following primary antibodies: rabbit anti-a-synuclein (EMD
Millipore), mouse anti-a-synuclein (Thermo Fisher), rabbit anti-
a-synuclein (phospho-S129, Abcam), rabbit anti-MMP-2 (Cell
Signaling Technology, Beverly, MA, http://www.cellsignal.com),
rabbit anti-caspase-3 (Cell Signaling Technology), and rabbit anti-
a-tubulin (Santa Cruz Biotechnology). As secondary antibodies,
a 1:10,000 dilution of horseradish peroxidase (HRP)-conjugated
goat anti-rabbit antibody (GenDEPOT) and anti-mouse antibody
(GenDEPOT) were used. Antigen-antibody complexes were visu-
alized with a chemiluminescence system (Santa Cruz Biotechnol-
ogy), followed by exposure to x-ray film (Fujifilm Advanced
Research Laboratories) and ImageQuant LAS-4000 (GE Health-
care). For semiquantitative analysis, immunoblotting band densi-
ties were measured by computer imaging.
Measurement of Oligomeric a-Synuclein
Oligomeric a-synuclein was measured by using a high-sensitivity
oligomeric a-synuclein ELISA kit (MyBioSource, San Diego, CA,
https://www.mybiosource.com). A total of 50 ml of each diluted
sample and standard included in the kit was applied tomicrotiter
plates precoated with antibody that specifically recognized the
oligomeric a-synuclein peptides. The plate was incubated with
100ml per well of HRP-conjugate reagent for 1 hour at 37°C. After
washing, 350 ml of wash solutions was added to each well, and
then invert plate dried by hitting the plate until no moisture
appeared. The substratewas added and incubated for 15minutes
at 37°C, and then the reaction was stopped with stop solution.
The color reaction was measured with an automatic ELISAmicro-
plate reader with the wavelength set at 450 nm. The software
(Bio-Rad) was used to create standard curves and calculate the
concentration of the samples.
Measurement of a-Synuclein
The amount of a-synuclein was measured by using a sandwich
ELISA kit (AnaSpec, Fremont, CA, http://www.anaspec.com). A
total of 10 ml of each diluted sample and standard included
in thekitwereappliedtomicrotiterplatesprecoatedwithantibody
that specifically recognizeda-synuclein.After anovernight incuba-
tion at 4°C and washing, a detection antibody indirectly linked to
an enzyme was applied. After incubation and washing, 350 ml of
wash solution was added to each well and then invert plate dried
by hitting the plate until no moisture appeared. The substrate
was added and incubated for 15 minutes at 37°C, and then
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the reaction was stopped with stop solution. The color reaction
wasmeasuredwith an automatic ELISAmicroplate reader (BioTek,
Winooski, VT, http://www.biotek.com)with thewavelength set at
450 nm. The software (Bio-Rad) was used to create standard
curves and to calculate the concentration of the samples.
Stereological Cell Counts
TH-stained neurons were counted in the right and left substantia
nigra pars compacta (SNpc) of every fourth section throughout
the entire extent of the SNpc. Each midbrain section was viewed
at low power at a random start, and then the number of TH-
stainedcellswas countedathighpower. Toavoiddouble counting
of neurons with unusual shapes, TH-stained cells were counted
only when their nuclei were optimally visualized, which occurred
only in one focal plane. After all of the TH-stained neurons were
counted, the total numbers of TH-stained neurons in the SNpc
were calculated by using the formula described [29].
Statistical Analysis
The group means were compared using the Mann-Whitney U
test for pairs and the Kruskal-Wallis analysis for multiple groups.
p values less than .05 were considered statistically significant.
Statistical analyses were performed by using commercially
available software (SPSS Version 12.0; IBM, Armonk, NY, http://
www.ibm.com).
RESULTS
MSC-CM Disassembles a-Synuclein Aggregates
TodeterminewhetherMSCscandegradea-synuclein aggregates,
a-synuclein fibrils were incubated in freshmedium, SH-SY5Y-CM,
and MSC-CM. On analysis of thioflavin fluorescence, which is
widely used to bind to fibrillar structures, the intensity of
a-synuclein aggregates was markedly higher in fresh medium,
whereasa-synucleinaggregatesweresignificantlydecreased inthe
MSC-CMcomparedwith freshor SH-SY5Y-CM (Fig. 1A). In addition,
electronmicroscopy (EM) analysis showed that a-synuclein aggre-
gates incubated in freshmedium exhibited the presence of long fi-
brils as well as large web-like networks composed of many fibrils,
whereasa-synuclein aggregates in SH-SY5Y- orMSC-CM showed a
variety of smaller and apparently amorphous aggregates corre-
sponding to nonfibrillar species (Fig. 1B). The amorphous aggre-
gates of nonfibrillar forms were more prominent in MSC-CM
compared with SH-SY5Y-CM. Next, we performed Western blot
analysis to determine themodulatory effects ofMSCs on the solu-
ble and insoluble fractions of a-synuclein. a-Synuclein aggregates
incubated with fresh medium or SH-SY5Y-CM were composed
mainlyof the insoluble fractionofa-synuclein,whereas theportion
of insoluble a-synuclein fraction was markedly decreased in MSC-
CM compared with fresh or SH-SY5Y-CM (Fig. 1C). In addition, the
levels of a-synuclein oligomers in soluble and total fractions were
significantlydecreased inMSC-CMcomparedwith freshmediumor
SH-SY5Y-CM (Fig. 1D).
MSC-Mediated a-Synuclein Cleavage Increases
Cellular Viability
To visualize the endocytosis ofa-synuclein,weusedAlexa 488 flu-
orescently labeled a-synuclein fibrils. Alexa 488-labeled a-synuclein
fibrils were incubated with fresh medium, SH-SY5Y-CM, or
MSC-CM, and then SH-SY5Y cells were treated with eachmedium
for 72hours. Immunofluorescence analysis indicated that thema-
jority of Alexa 488-labeled a-synuclein fibrils were rapidly inter-
nalized into the cytoplasm in fresh medium and SH-SY5Y-CM,
whereas intracellular uptake of Alexa 488-labeled a-synuclein
was markedly decreased in MSC-CM (Fig. 2A). In addition, West-
ern blot analysis showed that the amount of a-synuclein in SH-
SY5Y cells was significantly lower in MSC-CM compared with
fresh medium or SH-SY5Y-CM, further confirming that MSC-CM
significantly blocked endocytosis of extracellular a-synuclein (Fig.
2B). Next, to evaluate the cytotoxic consequences of a-synuclein
internalization, we compared neuronal viability of SH-SY5Y cells
treated with fresh medium, SH-SY5Y-CM, or MSC-CM for 24
and 48 hours by MTT assay. When SH-SY5Y cells were treated
with eachmediumfor24hours,neuronal viabilitydidnotdiffer sig-
nificantly among the groups (Fig. 2C). However, SH-SY5Y cell viabil-
itywassignificantly increased inMSC-CMafter48hoursof treatment
compared with fresh medium and SH-SY5Y-CM (Fig. 2D).
a-Synuclein Fibrils Are Cleaved by the MSC-Derived
Protein MMP-2
To determine proteins secreted from MSCs, we collected three
independent samples of fresh medium, SH-SY5Y-CM, and MSC-
CM for 2D-PAGE and MALDI-TOF/MS proteomics. On the 2D-
PAGE gel of total protein extracted from each medium at 72
hours, spot intensities and patterns were largely similar between
independent samples from the SH-SY5Y-CM andMSC-CM groups
(supplemental online Fig. 2).MMP-2was expressed in bothMSCs
and SH-SY5Y cells; however, the expression level of MMP-2 was
much higher in MSCs relative to SH-SY5Y cells (supplemental
online Fig. 3). a-Synuclein fibrils were incubated with MMP-2
for 72 hours to examine their effects ona-synuclein degradation.
EM analysis showed that a-synuclein aggregates in the presence
of MMP-2 exhibited a large portion of smaller and apparently
amorphous aggregates compared with the absence of MMP-2
(Fig. 3A). In a ThT fluorescence assay,a-synuclein aggregates that
exhibited b-sheet formation in the presence of MMP-2 were
significantly decreased compared with those in the absence of
MMP-2 (Fig. 3B). Consistentwith these results,Westernblot anal-
ysis indicated thatMMP-2 treatment led to a marked decrease in
the insoluble a-synuclein fraction from a-synuclein aggregates,
whichwerecomposedmainlyof the insoluble fraction(Fig.3C).Next,
to confirm that MMP-2 had a cleavage effect on a-synuclein aggre-
gates, we used an MMP-2 siRNA construct to knock down MMP-2
expression in MSCs. As expected, MMP-2 expression was markedly
decreased inMMP-2siRNA-treatedMSCs(supplementalonlineFig.4).
The ThT fluorescence assay indicated that when a-synuclein fibrils
were incubatedwith CMofMMP-2 siRNA-treatedMSCs, the inten-
sity ofa-synuclein aggregateswas significantly increased relative to
incubation inMSC-CM(Fig. 3D).Westernblot analysis revealed that
MMP-2 siRNA-treated medium increased the level of the a-synu-
clein insoluble fraction with a concomitant reduction in the soluble
fraction compared with MSC-CM, suggesting that MMP-2 could
markedly enhance a-synuclein cleavage (Fig. 3E). In addition,
MMP-2 siRNA-treated medium significantly increased oligomeric
a-synuclein levels in soluble and total fractions compared with
MSC-CM or MMP-2 treatment (Fig. 3F). Finally, to evaluate the ef-
fects of MSCs on neuronal viability after knocking down of MMP-2
expression, SH-SY5Y cells were treated with CM of MMP-2 siRNA-
treated MSCs that had been preincubated with a-synuclein fibrils.
SH-SY5Y cell viability that was significantly increased in MSC-CM
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relative to freshmediumwas prominently attenuated in the pres-
ence of MMP-2 siRNA-treated MSC-CM (Fig. 3G). These results
suggested that the MSC-derived factor, MMP-2, likely accelera-
ted degradation of a-synuclein fibrils. However, the intensity of
a-synuclein aggregates, the proportion of the insoluble fraction,
andneuronal viability inMMP-2 siRNA-treatedMSC-CMwerenot
comparable to the corresponding values in fresh medium or SH-
SY5Y-CM (Fig. 3D–3G), suggesting that other soluble factors in ad-
dition to MMP-2 may be involved in a-synuclein aggregate
modulation.
MSCs Express MMP-2 and Could Modulate a-Synuclein
Expression in MPTP-Treated Parkinsonian Animals
To evaluate whether MSCs could modulate MMP-2 expression in
a MPTP-induced animal model of PD, we attempted to identify
MSCs in the midbrain using human-specific NuMA antibody. Im-
munohistochemical analysis revealed that NuMA-positive cells
were not detected in only MPTP-treated animals, whereas ap-
proximately 0.9% of injected MSCs that were coimmunostained
with MMP-2 were observed in the MSC treatment group (Fig.
4A). The expression of MMP-2 in the midbrain was significantly
decreased in MPTP-treated animals compared with controls;
however, MSC administration markedly restored MMP-2 ex-
pression in MPTP-treated animals (Fig. 4B). In addition, MPTP
treatment significantly increased the immunoreactivity of
a-synuclein with accumulation of aggregated a-synuclein in the
TH-positive neurons and the overall level of total a-synuclein
anda-synuclein oligomers in themidbrain (Fig. 4B–4D).However,
MSC administration in MPTP-treated animals significantly atten-
uated accumulation of aggregated a-synuclein and the expression
of total a-synuclein and the levels of a-synuclein oligomers in the
midbrain compared with MPTP-treated animals (Fig. 4B–4D).
Moreover, MSC treatment in MPTP-treated animals significantly
decreased the expression of cleaved caspase-3 fragment and in-
creased survival of dopaminergic neurons in the midbrain com-
pared with only MPTP-treated animals (Fig. 4E, 4F).
MSCsDisassembleExtracellulara-SynucleinAggregates
via Increased MMP-2 Expression in a-Synuclein-
Inoculated Animals
In a-synuclein-inoculated animals, NuMA-positive cells were
coimmunostained with MMP-2 in the MSC-treated animals
(Fig. 5A), and the expression of MMP-2 in the cortex was signifi-
cantly increased in the MSC-treated animals relative to only
a-synuclein-inoculated animals (Fig. 5B). Additionally, MSC ad-
ministration in a-synuclein-inoculated animals significantly at-
tenuated the amount of phosphorylated a-synuclein and the
levels of total and soluble a-synuclein oligomers in the cortex
Figure 1. MSCs disassemble a-synuclein fibril formation. (A): Analysis of ThT fluorescence showed that the intensity of aS aggregates was
higher in freshmedium,whereasaSaggregatesweredecreased in theMSC-CM. (B):Anelectronmicroscopy analysis showed thataSaggregates
incubated in the fresh medium, whereas the amorphous aggregates of nonfibrillar forms were observed in MSC-CM compared with SH-SY5Y-
CM. (C): The portion of insoluble aS fraction was decreased in MSC-CM. (D): The levels of oligomeric aS in soluble and total fractions were
decreased in MSC-CM compared with fresh medium or SH-SY5Y-CM. All data are presented as the means6 SE. p, p, .05; pp, p, .01. Scale
bar = 200nm.Abbreviations:MSC-CM, conditionedmediumobtained frommesenchymal stemcells;aS,a-synuclein; SH-SY5Y-CM, conditioned
medium obtained from SH-SY5Y cells; ThT, Thioflavin T.
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Figure 2. MSCs significantly increase cellular viability. (A): Immunofluorescence analysis revealed that the majority of Alexa 488-labeled aS
fibrils were internalized into intracellular cytoplasm in fresh medium, SH-SY5Y-CM, and MSC-CM. (B): Western blotting showed that the ex-
pression of aS was reduced in MSC-CM. (C, D): Cell viability among the groups of each medium after 24 hour (C) or 48 hour (D) treatment.
All data are presented as the means 6 SE. p, p , .05; pp, p , .01. Scale bar = 20 mm. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole;
MSC-CM, conditioned medium obtained from mesenchymal stem cells; aS, a-synuclein; SH-SY5Y-CM, conditioned medium obtained from
SH-SY5Y cells.
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compared with a-synuclein-inoculated animals (Fig. 5B, 5C).
Moreover, MSC treatment in the a-synuclein-inoculated brain
significantly attenuated phosphorylated a-synuclein immunore-
activity with an increase in MMP-2 immunoreactivity (Fig. 5D),
suggesting that MSCs and MSC-derived MMP-2 inhibit the
induction of pathogenic a-synuclein by disassembling exoge-
nous a-synuclein aggregates. Consequently, MSC treatment
in a-synuclein-inoculated animals significantly decreased the
expression of cleaved caspase-3 fragment in the cortex, compared
with only a-synuclein-inoculated animals (Fig. 5E). We further ex-
amined the effects of MSCs on proteolysis of a-synuclein aggre-
gates after stereotaxic inoculation of a-synuclein fibrils into the
striatum. Consistent with previous findings, MSC treatment in
a-synuclein-inoculated animals markedly increased MMP-2 ex-
pression in the striatum,which induced attenuation of the amount
of phosphorylateda-synuclein anda-synuclein oligomerswith de-
creased caspase-3 expression (supplemental online Fig. 5).
a-Synuclein Aggregate Formation Is Decreased by
MSC-CMandMMP-2 ina-Synuclein-InoculatedAnimals
To elucidate the modulatory effects of MSCs and MMP-2 on
extracellular a-synuclein aggregates, an endocytosis inhibitor
(dynasore) and synthetic a-synuclein were coinjected into the
neocortex to avoid intracellular internalization as much as possi-
ble. After 24 hours, fresh medium, MSC-CM, and MMP-2 were
injected into the same site, and a-synuclein aggregates were
assessed around the injection site 72 hours later. Immunohisto-
chemical analysis showed that both a-synuclein and ThT immuno-
reactivities in fresh-medium-treated animals were prominent and
extendedbeyond the injection site. However, animals administered
MSC-CM showed markedly reduced levels of immunoreactivity for
both a-synuclein and ThT, and the immunoreactivity was localized
to the injection site, indicating thatMSC-CM could attenuate extra-
cellular a-synuclein aggregate formation. Similar to MSC-CM,
MMP-2 administration exhibited a modulation of extracellular
a-synuclein aggregates, with deceased and localized immuno-
reactivity for aggregated a-synuclein (Fig. 6A). OnWestern blotting,
the proportion of insoluble a-synuclein fraction relative to the solu-
ble form was increased in fresh medium-treated animals, whereas
the insoluble a-synuclein fraction was significantly decreased in an-
imals receiving MSC-CM or MMP-2 (Fig. 6B). Western blot analysis
usinghuman-specifica-synucleinantibodyalsorevealedquitesimilar
patterns of inoculateda-synuclein amounts afterMSC-CMorMMP-
2 treatment (supplemental online Fig. 6). The levels of a-synuclein
oligomers in soluble and total fractionswere lower in animals receiv-
ing MSC-CM or MMP-2 than fresh medium-treated animals. These
a-synucleinoligomer levelsweremuch lower inMSC-treatedanimals
relative to MMP-2-treated animals (Fig. 6C). Additionally, the cleav-
age of procaspase-3 into the active subunits was clearly observed in
animals receiving fresh medium compared with animals receiving
MSC-CM or MMP-2 (Fig. 6D).
DISCUSSION
The present study demonstrated that MSCs degraded the aggre-
gated form of a-synuclein both in cellular and animal models of
enricheda-synuclein and exerted a prosurvival effect on neurons
through proteolysis of aggregated a-synuclein. In addition, we
showed thatMMP-2, a factor derived fromMSCs, plays an impor-
tant role in the disassembly of aggregated a-synuclein in these
models. Our data suggest that the cleavage effect of MSC-derived
soluble factors is responsible for attenuation of extracellular
Figure 3. Mesenchymal stem cell-derivedMMP-2 accelerates degradation of a-synuclein fibrils. (A): An electronmicroscopy analysis showed
that a-synuclein (aS) aggregates in the presence of MMP-2 exhibited a large portion of smaller and apparently amorphous aggregates. (B):On
the thioflavin fluorescence assay, aS aggregates in the presence of MMP-2 were decreased compared with aS aggregates alone. (C):Western
blotting revealed that MMP-2 treatment led to a decrease in the portion of insoluble aS fraction. (D–F):When aS fibrils were incubated with
MMP-2 siRNA-treatedMSC-CM, the intensity ofaS aggregateswas increased relative toMSC-CM.MMP-2 siRNA-treatedmedium increased the
expression of aS insoluble fractions and oligomeric aS levels compared withMSC-CM orMMP-2 treatment . (G): SH-SY5Y cell viability that was
increased inMSC-CM relative to freshmediumwas attenuated in the presence ofMMP-2 siRNA-treated medium. All data are presented as the
means6 SE. p, p, .05; pp, p, .01. Scale bar = 200 nm. Abbreviations: MMP-2, matrix metalloproteinase-2; MSC-CM, conditioned medium
obtained from mesenchymal stem cells; aS, a-synuclein; siRNA, small interfering RNA; ThT, Thioflavin T.
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a-synuclein aggregates, which may be applicable to future clinical
strategies for treatment of PD patients.
It is well known that a-synuclein has a tendency to aggregate
and accumulate, thus forming small intracellular aggregates,
which would lead to an increase in cellular toxicity and cell death
in various types of a-synucleinopathies [30–32]. More impor-
tantly, recent studies have provided convincing evidence for
cell-to-cell propagation of a-synuclein, showing that a-synuclein
and its aggregates are released from neuronal cells via exocytosis
[33, 34], and neurons and glial cells have the ability to take up ex-
tracellular a-synuclein aggregates through endocytosis [35, 36].
In terms of their prion-like behavior, extracellulara-synuclein ag-
gregates seem to play key roles in the pathogenesis and progres-
sion of PD, and treatment strategies focused on modulation of
extracellular a-synuclein transmission would be clinically rele-
vant for PD. In this regard, the results of immunotherapy targeting
aggregateda-synuclein in animalmodels of Lewybodydiseases are
very suggestive, because antibodies againsta-synuclein canmodu-
late aggregated a-synuclein at several steps of accumulation and
propagation [37,38].Specifically,antibodiescanrecognizea-synuclein
oligomers accumulating in the neuronal membrane and, after
internalization, enhance degradation of a-synuclein via autophagy
[39, 40]. Furthermore, during extracellular propagation a-synuclein,
circulating antibodies enhance removal of extracellular a-synuclein
aggregatesandthusmodulate theirpropagation [38,41]. Inaddition,
several experimental studies showed that rifampicin, a common
antibiotic used in the treatment of tuberculosis and leprosy, has
the ability to inhibita-synuclein aggregation and disaggregate pre-
formed fibrils and reduce a-synuclein aggregation in a-synuclein
transgenic mice with decreased neurodegeneration [42, 43].
Therefore, a therapeutic strategy to enhance removal of extracel-
lulara-synuclein aggregatesmay be an important pharmacological
target in disease-modifying treatment strategies for PD.
Several studies have demonstrated that MSCs exert neuro-
protective effects by secretion of neurotropic molecules that
directly or indirectly canmodulate neurodegenerativemicroenvi-
ronment [44, 45].Additionally,MSCsare known to secrete several
molecules into the neural niche microenvironment, which could
promote endogenous neural repair [46, 47]. Moreover, MSCs
have the potential to facilitate proteolysis against the assembled
protein structures [48]. In the present study, we found thatMSCs
have the ability to disaggregate preformed fibrils of a-synuclein
Figure 4. MSCs modulate a-synuclein in MPTP-treated Parkinsonian animals through induction of MMP-2. (A): Immunohistochemical analysis
revealed thatNuMA-positive cellswere coimmunostainedwithMMP-2 in theMSC-treated animals. (B):MSCadministrationdecreasedaS expres-
sion with a restoration ofMMP-2 expression inMPTP-treated animals. (C):MSC administration inMPTP-treated animals decreased the immuno-
reactivity ofaS with accumulation of aggregated aS (white arrows) in the TH-positive neurons. (D):MSC administration in MPTP-treated animals
decreased the levels of soluble and totalaSoligomers in themidbrain comparedwithonlyMPTP-treated animals. (E, F):MSC treatment decreased
theexpressionofcleavedcaspase-3 fragmentand increased the survival ofTH-positiveneurons comparedwithonlyMPTP-treatedanimals.All data
are presentedas themeans6 SE.p,p, .05;pp,p, .01. Scale bars = 10mm.Abbreviations:DAPI, 49,6-diamidino-2-phenylindole; L, left substantia
nigra pars compacta; MMP-2, matrix metalloproteinase-2; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MSC, mesenchymal stem cell;
NuMA, anti-nuclear mitotic apparatus protein; R, right substantia nigra pars compacta; aS, a-synuclein; TH, anti-tyrosine hydroxylase.
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and thus lead to a decrease in level of the insoluble form of
a-synuclein, which was accompanied by increased neuronal sur-
vivals. In the in vitro experiments, preformed a-synuclein aggre-
gates incubated with MSC-CM showed marked disassembly, and
the ratio of insoluble and soluble forms of a-synuclein was de-
creased compared with those incubated with fresh medium or
SH-SY5Y-CM. Interestingly, the present study showed that rem-
nant a-synuclein in the medium could be internalized into neu-
rons when cocultured with neuronal cells. As expected, the
amounts of a-synuclein aggregates located in the neuronal cyto-
plasm were significantly decreased in MSC-CM relative to fresh
mediumor SH-SY5Y-CM,which led to a significant increase inneu-
ronal viability. The modulatory effect of MSCs on a-synuclein
aggregates was further supported by in vivo experiments. MSC
treatment in a neurotoxin-induced animal model of PD signifi-
cantly attenuated the expression of total and oligomeric forms
of a-synuclein in the midbrain compared with neurotoxin treat-
ment alone, which led to decreased caspase-3 expression and do-
paminergic neuronal loss. Moreover, in a-synuclein-inoculated
animals, MSCs inhibited the induction of pathogenic a-synuclein
in cortical neurons by disassembling exogenous a-synuclein
aggregates and, consequently, attenuated apoptotic cell death
signaling. In addition, administration of MSC-CM markedly de-
creased the extent of inoculated a-synuclein aggregates and sig-
nificantly decreased expression of the insoluble and oligomeric
formsofa-synuclein in animals treatedwithenricheda-synuclein
compared with fresh medium. Accordingly, the present study
providedadditional evidence thatMSCsexert neuroprotective ef-
fects in a model of PD through the disassembly of aggregated
a-synuclein.
In the present study, MALDI-TOF/MS analysis indicated that
MMP-2 is one of theMSC-derived soluble factors that is involved
in proteolysis of aggregateda-synuclein and its related neurotro-
phic properties. MMPs are a family of zinc-dependent endopep-
tidases that are functionally important for the extracellular space
by degrading components of the extracellular matrix and base-
ment membranes in disease processes [49]. The MMP genes
are transcriptionally responsive to a wide variety of growth fac-
tors, cytokines, and reactive oxygen species [50, 51]. Recently, ac-
cumulating studies showed that MMPs are major culprits in the
pathogenesis of PDmediatedbyneuroinflammation, apoptotic sig-
naling indopaminergicneurons,blood-brainbarrierdisruption,and
proteolysis of a-synuclein aggregates [52, 53]. With regard to pro-
teolytic effects ofMMP on aggregated a-synuclein, MMP-1 and -3
Figure 5. MSC treatment attenuates extracellular a-synuclein aggregates in a-synuclein-inoculated animals. (A): Immunohistochemical anal-
ysis revealed that NuMA-positive cells were coimmunostained with MMP-2 in the MSC-treated animals. (B): MSC treatment decreased the
expression of phosphorylated aS and restored MMP-2 expression in aS-inoculated animals. (C): MSC administration decreased the levels
of soluble and total aS oligomers in the cortex compared with only aS-inoculated animals. (D): MSC treatment in aS-inoculated animals
decreased the immunoreactivity of phosphorylated aS and increased the immunoreactivity of MMP-2. (E):MSC treatment decreased the ex-
pression of cleaved caspase-3 fragment comparedwith onlyaS-inoculated animals. All data are presented as themeans6 SE. pp, p, .01. Scale
bars = 10mm. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; MMP-2, matrix metalloproteinase-2; MSC, mesenchymal stem cell; NuMA,
anti-nuclear mitotic apparatus protein; p-aS, phosphorylated a-synuclein; aS, a-synuclein.
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havebeenshowntoenhancea-synucleinaggregationvia increased
formation of the aggregation-prone a-synuclein domain resulting
from limited proteolysis [54, 55]. Interestingly, we demonstrated
in the present study that the MSC-derived factor, MMP-2, could
cleave preformed fibrils of a-synuclein and then induce a compo-
sitional change of a-synuclein fibrils to a smaller proportion of in-
soluble and oligomeric forms. Thismodulatory effect ofMMP-2 on
aggregated a-synuclein was further supported by MMP-2 siRNA
treatment in vitro, showing that MMP-2 siRNA treatment of
MSC-CM resulted in loss of its proteolytic effects on aggregated
a-synuclein and its associated prosurvival effects on neuronal
cells. Furthermore, our in vivo data clearly demonstrated that
MMP-2 was coexpressed within MSCs injected intravenously,
and MSC treatment significantly increased the expression of
MMP-2 in MPTP-treated and a-synuclein-inoculated animals,
which finally attenuated the expression of a-synuclein and
the induction of pathogenic a-synuclein. In animals treated
with enriched a-synuclein, this modulatory effect of MMP-2
on aggregated a-synuclein seemed to be comparable to those
of MSCs, by showing that MMP-2 treatment markedly decreased
the extent of inoculateda-synuclein aggregates, as well as expres-
sion of the insoluble and oligomeric forms of a-synuclein, com-
pared with fresh medium.
In agreementwith our findings, a previous postmortem study
indicated that the levels ofMMP-2were significantly decreased in
the substantia nigra of PD patients compared with age-matched
controls [56]. In addition, MMP-2 appears to play an important
role in degrading Alzheimer disease (AD) pathologies of Ab40
and Ab42 in cellular and animal models [57, 58]. Mlekusch and
Humpel [59] suggested that a decrease in the level of MMP-2
in cerebrospinal fluid of AD patients might contribute to the ac-
cumulation of insoluble Ab peptide in plaques. Accordingly, the
present study provided convincing evidence that MMP-2, as
one MSC-derived soluble factor, can modulate the pathogenic
microenvironments of PD through proteolysis of aggregated
a-synuclein into soluble forms.
Even thoughMMP-2had thepotential to facilitateproteolysis
against aggregated a-synuclein, the ability of MMP-2 was not
Figure 6. MSC-CM and MMP-2 attenuate extracellular a-synuclein aggregates in a-synuclein-inoculated animals. (A): Both aS and ThT immuno-
reactivities in fresh medium-treated animals were prominent and extended beyond the injection site, whereas these immunoreactivities were lo-
calized to the injection site in animals administeredMSC-CM andMMP-2. The area shown in the yellow box in the upper right is enlarged in lower.
(B, C): The levels of insoluble and oligomeric aS were decreased in animals receivingMSC-CM orMMP-2 compared with fresh medium-treated an-
imals. (D): The cleaved caspase-3 was clearly observed in animals receiving fresh medium compared with animals receiving MSC-CM orMMP-2. All
dataarepresentedas themeans6SE.p,p, .05;pp,p, .01.Scalebars=50and10mm.Abbreviations:DAPI, 49,6-diamidino-2-phenylindole;MMP-2,
matrix metalloproteinase-2; MSC-CM, conditioned medium obtained from mesenchymal stem cells; aS, a-synuclein; ThT, Thioflavin T.
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comparable to that of MSCs. According to our in vitro data, the
modulatory effect of MSCs on aggregated a-synuclein and their
related prosurvival effect on neuronal cells were not completely
blocked by MMP-2 siRNA treatment of CM, suggesting the exis-
tence of other MSC-derived soluble factors involved in aggre-
gated a-synuclein cleavage. For example, several candidate
proteases have been shown to cleave and degrade a-synuclein,
including neurosin, cathepsin D, and plasmin [60–62]. In addition,
several neurotrophic factors secreted from MSCs would act as
strong modulators of neuronal cell survival and neuroprotection
against the PD-relatedmicroenvironment [63]. Additional studies
are therefore required to identify MSC-derived small molecules
responsible for a-synuclein cleavage that would have clinical po-
tential for the development of disease-modifying therapeutic
strategies for use in PD.
Because clinical and experimental data convincingly sug-
gest a crucial role for a-synuclein aggregation in the pathogen-
esis of PD, therapeutic strategies focusing on the disassembly
of a-synuclein aggregation have been investigated in both pre-
clinical and clinical fields [64, 65]. Strategies that intervenewith
toxic protein aggregation can be divided into seed clearance,
inhibition of aggregation formation, and aggregate clearance.
Of these, the present data provide the role ofMSCs in aggregate
clearance, concomitantly showing that direct disassembly of
extracellular a-synuclein aggregation does not lead to increases in
the levels of toxic aggregates. Considering our previous data indicat-
ing that, in addition to their advantages in clinical applications,MSCs
have a modulatory role on intracellular a-synuclein aggregation
through autophagy [21], a therapeutic perspective suggests that
the use of MSCs or MSC-derived soluble factors as pharmacological
modulators of a-synuclein aggregation may be an effective thera-
peutic approach for PD.
CONCLUSION
The present data indicated that MSCs exert neuroprotective
properties through proteolysis of aggregated a-synuclein into
soluble forms, and MMP-2 may be the principal soluble factor
released by MSCs responsible for proteolysis of a-synuclein ag-
gregates. The present study suggests that the disassembly of
a-synuclein aggregation to control PD-related microenviron-
ments using MSCs may have a significant impact on future PD
treatment strategies.
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